In another shocker, FDA rejects BioMarin’s hemophilia A gene therapy, demanding more data on durability

John Carroll

Editor & Founder

It turns out that BioMarin’s rivals aren’t the only ones with doubts about the durability of BioMarin’s hemophilia A gene therapy. Regulators at the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In another shocker, FDA rejects BioMarin’s hemophilia A gene therapy, demanding more data on durability

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

In an­oth­er shock­er, FDA re­jects Bio­Marin’s he­mo­phil­ia A gene ther­a­py, de­mand­ing more da­ta on dura­bil­i­ty

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

In another shocker, FDA rejects BioMarin’s hemophilia A gene therapy, demanding more data on durability

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings